 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ISM004-1057D / Insilico Medicine, Fosun Pharma
New P1 trial, Monotherapy, Metastases: Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov) - Jun 6, 2024
P1, N=60, Recruiting, Sponsor: InSilico Medicine Hong Kong Limited
- ISM004-1057D / Insilico Medicine, Fosun Pharma
Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1680;
ISM8207 was well-tolerated with favorable ADME and PK properties. Conclusions These data strongly support the clinical evaluation of ISM8207 as a novel cancer immunotherapy in TNBC and B-NHL.